Skip to main content
Premium Trial:

Request an Annual Quote

Intermountain Healthcare Taps Kailos Genetics for PGx Testing

This article has been updated from a previous version to correct the nature of the services Kailos is providing to Intermountain.

NEW YORK – Kailos Genetics, a CLIA-certified genetic sequencing company, has entered into a partnership with Intermountain Healthcare to establish a pharmacogenetic testing platform for the healthcare network.

Under the agreement, Intermountain will be able to implement Kailos' PGxComplete next-generation sequencing methodology in its laboratory for pharmacogenetic testing. Through the partnership, Intermountain will have access to PGxComplete reagents for capturing and enriching specific portions of the human genome, sequencing on an Illumina MiSeq or NextSeq instrument, and analyzing the data with the Kailos Blue cloud-based LIMS-to-analysis software solution, Troy Moore, chief scientific officer at Kailos, said in an email.

"We combine our expertise in both genetic panel design and Illumina sequencing technology to provide robust, up-to-date pharmacogenetics data that is securely and directly transferred to most Laboratory Information Management Systems," Kailos CEO Brian Pollock said in a statement.

Kailos was founded in 2010 and is located at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. Intermountain Healthcare is a not-for-profit health system serving Utah, southern Idaho, and southern Nevada. Headquartered in Salt Lake City, Utah, it consists of 24 hospitals, 2,400 physicians, and approximately 160 clinics.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.